RWD SIG

Purpose

To increase collaboration and enhance awareness of strategies and methodologies applied in the utilization of Real World Data in the pharmaceutical industry.

Objectives

Our objectives include:

  • Facilitate sharing of case studies and experiences in this area
  • Collate and summarise publications, articles, presentations, training
  • Identify emerging news and trends
  • Organise and/or participate in workshops related to RWD
  • Collaborate with key stakeholder groups (EFSPI/PSI, EFPIA, ISPOR,  regulatory and academia)
  • Provide comments on RWD related guidelines, e.g. country-specific methods guidelines, FDA methods guidelines, ISPOR etc.
  • Develop/highlight best practices and recommendations
  • Influence industry practice and acceptance of approaches by regulators and other stakeholders

 

Who we are

NameCompany/Institution
Anny Stari (Chair)GSK
Peter Almgren

LEO Pharma

Anders Berglund 

Daiichi-Sankyo

Tobias Bluhmki 

Bristol Myers Squibb
Imi FaghmousKite Gilead
Fiona GrimsonUCB
Randi GrønNovo Nordisk
Richard GroveGSK

Alessandro Guasconi 

Chiesi Farmaceutici S.p.A.
Deepak Parashar  

Warwick University

Kostas Sechidis 

Novartis
Claire SmithAstraZeneca
Aijing ShangRoche
Barbara TorlinskaUniversity of Birmingham

Sudhir Venkatesan

AstraZeneca
Huajun WangGSK

Jixian Wang

Bristol Myers Squibb

Qing Wang 

Roche

Josephine Wolfram 

Astellas

Call for members

Frequency of Meetings

Monthly teleconferences

Upcoming Events

Latest Jobs